Breaking Down Cancer

Illustration: A. Canamucio Orphan diseases are those with patient populations so small that drug companies generally don't make money if they come up with a remedy. The National Organization for Rare Disorders lists 1,100 of these afflictions in its database, from Aarskog syndrome, an extremely rare birth defect with structural abnormalities and mild mental retardation, to Zollinger Ellison syndrome, presenting gastric tumors that secrete excessive hormone amounts. Subsets of rare disorders, suc

Written byTerry Sharrer
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share


Illustration: A. Canamucio
Orphan diseases are those with patient populations so small that drug companies generally don't make money if they come up with a remedy. The National Organization for Rare Disorders lists 1,100 of these afflictions in its database, from Aarskog syndrome, an extremely rare birth defect with structural abnormalities and mild mental retardation, to Zollinger Ellison syndrome, presenting gastric tumors that secrete excessive hormone amounts. Subsets of rare disorders, such as leukodystrophy, may include only a handful of sufferers, and perhaps just one (documented).

Oddly, though, rare diseases may become the norm in the future of medicine, as genomics--in defining diseases by their genetic origins rather than physical symptoms--breaks down large patient populations to smaller and smaller groups, and perhaps eventually addressing individual expressions. Cancer, for example, is not one disease, nor even "many," but may be a historical term with as many forms as there are people ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies